1. Australian Institute of Health and Welfare (AIHW). ACIM (Australian Cancer Incidence and Mortality) 2012.
2. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer-2007 update of an ASCO practice guideline. J Clin Oncol 2007; 25: 1596–1605.
3. Strum S, Scholz M, McDermed J . The androgen deprivation syndrome: the incidence and severity in prostate cancer. Proc Am Soc Clin Oncol 1998; 17: 316.
4. Klotz L, Herr H, Morse M, Whitmore W . Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58: 2546–2550.
5. Bruchovsky N, Rennie P, Coldman A, Goldenberg S, To M, Lawson D . Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 2275–2282.